Charcot-Marie-Tooth Disease: This Company Just Got Critical Funding to Develop a Treatment
source: pixabay.com

Charcot-Marie-Tooth Disease: This Company Just Got Critical Funding to Develop a Treatment

According to a story from Charcot-Marie-Tooth News, the drug company DTx Pharma has recently obtained critical funding that will go towards the development of new RNA-based treatments for Charcot-Marie-Tooth disease…

Continue Reading Charcot-Marie-Tooth Disease: This Company Just Got Critical Funding to Develop a Treatment
X-Linked Severe Combined Immunodeficiency: Companies Announce Licensing Agreement for Gene Therapy Tech
source: pixabay.com

X-Linked Severe Combined Immunodeficiency: Companies Announce Licensing Agreement for Gene Therapy Tech

According to a story from BioSpace, SIRION Biotech GmbH and Mustang Bio, Inc. have announced a new agreement for licensing the use of SIRION's proprietary LentiBOOST™ technology for use by…

Continue Reading X-Linked Severe Combined Immunodeficiency: Companies Announce Licensing Agreement for Gene Therapy Tech
Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
source: pixabay.com

Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials

According to a story from BioSpace, the US Food and Drug Administration (FDA) recently announced that it has awarded grant funding that will go towards six clinical trials that will…

Continue Reading Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
source: pixabay.com

Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval

According to a story from BioSpace, the biopharmaceutical company Kite announced recently that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has released…

Continue Reading Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation
source: pixabay.com

Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma announced that two of its investigational treatments have recently received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation
Collaborative Study Highlights the Importance of Proteinuria in Focal Segmental Glomerulosclerosis
source: pixabay.com

Collaborative Study Highlights the Importance of Proteinuria in Focal Segmental Glomerulosclerosis

According to a story from BioSpace, a recent study conducted by the biotechnology company Goldfinch Bio in collaboration with academic partners is highlighting the importance of proteinuria in determining outcomes…

Continue Reading Collaborative Study Highlights the Importance of Proteinuria in Focal Segmental Glomerulosclerosis
RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community
source: pixabay.com

RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community

On October 15th, 2020, the Rare Disease Legislative Advocates (RDLA) held a webinar discussing some of the latest news regarding ongoing legislation that is most relevant to the rare disease…

Continue Reading RDLA Webinar Provides Vital Updates on Legislation Relevant to the Rare Disease Community
Experimental Gene Therapy for GM1 Gangliosidosis Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Gene Therapy for GM1 Gangliosidosis Earns Rare Pediatric Disease Designation

According to a story from BioSpace, the gene therapy company Axovant Gene Therapies Ltd. recently announced that it has been given Rare Pediatric Disease designation from the US Food and…

Continue Reading Experimental Gene Therapy for GM1 Gangliosidosis Earns Rare Pediatric Disease Designation
FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension
source: pixabay.com

FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension

According to a story from GlobeNewswire, the medical device company SoniVie announced recently that the US Food and Drug Administration (FDA) has granted approval for its Investigational Device Exemption (IDE).…

Continue Reading FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension
Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?
source: pixabay.com

Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?

On October 14th, 2020, the International Waldenström's Macroglobulinemia Foundation (IWMF) hosted a webinar featuring Dr. Irene Ghobrial of the Dana Farber Cancer Institute. The focus of her presentation was on…

Continue Reading Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?
Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment
source: pixabay.com

Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment

According to a story from GlobeNewswire, the biopharmaceutical company Immunomedics, Inc., has recently announced that its medication sacituzumab govitecan-hziy (marketed as Trodelvy) has recently earned Orphan Drug designation from the…

Continue Reading Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment
Gene Therapy Receives Rare Pediatric Disease Designation for Sandhoff Disease and Tay-Sachs Disease
source: pixabay.com

Gene Therapy Receives Rare Pediatric Disease Designation for Sandhoff Disease and Tay-Sachs Disease

According to a story from GlobeNewswire, the gene therapy company Axovant Gene Therapies Ltd. recently announced that its gene therapy AXO-AAV-GM2 has been given Rare Pediatric Disease designation by the…

Continue Reading Gene Therapy Receives Rare Pediatric Disease Designation for Sandhoff Disease and Tay-Sachs Disease
The Glanzmann’s Research Foundation: Dedicated to Finding a Cure
source: pixabay.com

The Glanzmann’s Research Foundation: Dedicated to Finding a Cure

Patient Worthy has recently begun a partnership with the Glanzmann's Research Foundation, a nonprofit patient organization dedicated to spreading awareness about Glanzmann's thrombasthenia and finding a cure. We spoke with…

Continue Reading The Glanzmann’s Research Foundation: Dedicated to Finding a Cure
Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation
source: pixabay.com

Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation

According to a story from GlobeNewswire, the biopharmaceutical company X4 Pharmaceuticals, Inc. has just announced that the US Food and Drug Administration (FDA) has granted its investigational product candidate mavorixafor…

Continue Reading Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation
Zeposia as a Treatment for Ulcerative Colitis Shows Positive Results in Phase 3 Trial
source: pixabay.com

Zeposia as a Treatment for Ulcerative Colitis Shows Positive Results in Phase 3 Trial

According to a story from Pharma Advancement, Bristol Myers Squibb recently announced encouraging findings from a phase 3 clinical trial. This study was testing its drug ozanimod (marketed as Zeposia)…

Continue Reading Zeposia as a Treatment for Ulcerative Colitis Shows Positive Results in Phase 3 Trial